Impact of Treatment Modality and Route of Administration on Cytokine Release Syndrome in Relapsed or Refractory Multiple Myeloma: A Meta‐Analysis
Clinical Pharmacology & Therapeutics · 2024-06 · 115 (6) · 1258-1268
DOI: 10.1002/cpt.3223 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 08.03.2024. Verfasst von Pooneh Soltantabar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Research and Development, Pfizer Inc, San Diego, California, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Cytokine Release Syndrome, Antibodies, Bispecific, B-Cell Maturation Antigen. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
B‐cell maturation antigen (BCMA)‐targeting immunotherapies (e.g., chimeric antigen receptor T cells (CAR‐T) and bispecific antibodies (BsAbs)) have achieved remarkable clinical responses in patients with relapsed and/or refractory multiple myeloma (RRMM). Their use is accompanied by exaggerated immune responses related to T‐cell activation and cytokine elevations leading to cytokine release syndrome (CRS) in some patients, which can be potentially life‐threatening. However, systematic evaluation of the risk of CRS with BCMA‐targeting BsAb and CAR‐T therapies, and comparisons across different routes of BsAb administration (intravenous (i.v.) vs. subcutaneous (s.c.)) have not previously been conducted. This study utilized a meta‐analysis approach to compare the CRS profile in BCMA‐targeting CAR‐T vs. BsAb immunotherapies administered either i.v. or s.c. in patients with RRMM. A total of 36 studies including 1,560 patients with RRMM treated with BCMA‐targeting CAR‐T and BsAb therapies were included in the analysis. The current analysis suggests that compared with BsAbs, CAR‐T therapies were associated with higher CRS incidences (88% vs. 59%), higher rates of grade ≥ 3 CRS (7% vs. 2%), longer CRS duration (5 vs. 2 days), and more prevalent tocilizumab use (44% vs. 25%). The proportion of CRS grade ≥ 3 may also be lower (0% vs. 4%) for BsAb therapies administered via the s.c. (3 studies, n = 311) vs. i.v. (5 studies, n = 338) route. This meta‐analysis suggests that different types of BCMA‐targeting immunotherapies and administration routes could result in a range of CRS incidence and severity that should be considered while evaluating the benefit–risk profiles of these therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Oncology Research and Development, Pfizer Inc, San Diego, California, USA.
- Department of Pharmaceutical Sciences, Washington State University, Spokane, Washington, USA.
ORCID-Profile: Pooneh Soltantabar, Mohamed Elmeliegy
Förderung
- Pfizer
Zitieren
APA
Soltantabar, P., Sharma, S., Wang, D., Lon, H. K., Czibere, A., Hickmann, A., & Elmeliegy, M. (2024). Impact of Treatment Modality and Route of Administration on Cytokine Release Syndrome in Relapsed or Refractory Multiple Myeloma: A Meta‐Analysis. Clinical Pharmacology & Therapeutics, 115(6), 1258-1268. https://doi.org/10.1002/cpt.3223
Vancouver
Soltantabar P, Sharma S, Wang D, Lon HK, Czibere A, Hickmann A, et al. Impact of Treatment Modality and Route of Administration on Cytokine Release Syndrome in Relapsed or Refractory Multiple Myeloma: A Meta‐Analysis. Clinical Pharmacology & Therapeutics. 2024;115(6):1258-1268. doi:10.1002/cpt.3223
BibTeX
@article{Soltantabar2024,
author = {Soltantabar, Pooneh and Sharma, Sheena and Wang, Diane and Lon, Hoi-Kei and Czibere, Akos and Hickmann, Anne and Elmeliegy, Mohamed},
title = {Impact of Treatment Modality and Route of Administration on Cytokine Release Syndrome in Relapsed or Refractory Multiple Myeloma: A Meta‐Analysis},
journal = {Clinical Pharmacology & Therapeutics},
year = {2024},
volume = {115},
number = {6},
pages = {1258--1268},
doi = {10.1002/cpt.3223}
}
EUVIMED